Insulin resistance, inflammation, and vascular disease in nondiabetic predialysis chronic kidney disease patients

Clinical Cardiology

Volumn 34, Issue 6, 2011, Pages 360-365

  Banerjee, Debasish ^a,b   Recio Mayoral, Alejandro ^b   Chitalia, Nihil ^a   Kaski, Juan Carlos ^b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTERY BLOOD FLOW; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CAROTID ARTERY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DILATION AND EVACUATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MALE; PATIENT; RISK FACTOR; VASCULAR DISEASE;

ADULT; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; KIDNEY DISEASES; LINEAR MODELS; LONDON; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TUNICA INTIMA; TUNICA MEDIA; VASCULAR DISEASES; VASODILATION;

EID: 79958272837     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20901     Document Type: Article

References (35)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003; 42: 1050-1065. (Pubitemid 37413751)
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-1305.
3. Fellström BC, Jardine AG, Schmieder RE, et al. for AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis [published correction appears in N Engl J Med. 2010;362:1450]. N Engl J Med. 2009; 360: 1395-1407.
4. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [published correction appears in N Engl J Med. 2005;353:1640]. N Engl J Med. 2005; 353: 238-248. (Pubitemid 41058323)
5. Duranti E, Imperiali P, Sasdelli M., Is hypertension a mortality risk factor in dialysis? Kidney Int Suppl. 1996; 55: S173-S174.
6. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999; 33: 507-517.
7. Zager PG, Nikolic J, Brown RH, et al. Medical Directors of Dialysis Clinic, Inc. "U" curve association of blood pressure and mortality in hemodialysis patients [published correction appears in Kidney Int. 1998;54:1417]. Kidney Int. 1998; 54: 561-569.
8. Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005; 16: 1091-1098. (Pubitemid 41710320)
9. Beddhu S, Nigwekar SU, Ma X, et al. Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. Nephrol Dial Transplant. 2009; 24: 2482-2488.
10. Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005; 68: 766-772. (Pubitemid 43323132)
11. Dogra G, Irish A, Chan D, et al. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis. 2006; 48: 926-934. (Pubitemid 44895366)
12. Levey AS, Bosch JP, Lewis JB, et al. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999; 130: 461-470. (Pubitemid 29135798)
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419. (Pubitemid 15018832)
14. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005; 23: 7-17. (Pubitemid 40128972)
15. Sidhu JS, Newey VR, Nassiri DK, et al. A rapid and reproducible on line automated technique to determine endothelial function. Heart. 2002; 88: 289-292. (Pubitemid 34913516)
16. Sidhu JS, Kaposzta Z, Markus HS, et al. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004; 24: 930-934. (Pubitemid 38620874)
17. Banerjee D, Recio-Mayoral A, Chitalia N, et al. Inflammation, insulin resistance and vascular disease in non-diabetic chronic kidney disease population. NDT Plus. 2010;(suppl 3): iii185.
18. Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35: 469-476. (Pubitemid 30124077)
19. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-658. (Pubitemid 29082891)
20. Dzurik R, Spustova V, Janekova K., The prevalence of insulin resistance in kidney disease patients before the development of renal failure. Nephron. 1995; 69: 281-285.
21. Muniyappa R, Montagnani M, Koh KK, et al. Cardiovascular actions of insulin. Endocr Rev. 2007; 28: 463-491. (Pubitemid 47236334)
22. Mahmud FH, Hill DJ, Cuerden MS, et al. Impaired vascular function in obese adolescents with insulin resistance. J Pediatr. 2009; 155: 678-682.
23. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium- dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992; 35: 771-776.
24. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996; 97: 2601-2610.
25. Tack CJ, Ong MK, Lutterman JA, et al. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance: effects of troglitazone. Diabetologia. 1998; 41: 569-576. (Pubitemid 28206828)
26. Valle JM, Estepa RM, Camacho RM, et al. Endothelial dysfunction is related to insulin resistance and inflammatory biomarker levels in obese prepubertal children. Eur J Endocrinol. 2007; 156: 497-502. (Pubitemid 46672652)
27. Tanigaki K, Mineo C, Yuhanna IS, et al. C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1. Circ Res. 2009; 104: 1275-1282.
28. Hamdy O, Ledbury S, Mullooly C, et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care. 2003; 26: 2119-2125. (Pubitemid 41184262)
29. Sanchez RA, Masnatta LD, Pesiney C, et al. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens. 2008; 26: 2393-2398.
30. Tezcan H, Yavuz D, Toprak A, et al. Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients. J Renin Angiotensin Aldosterone Syst. 2003; 4: 119-123. (Pubitemid 36790184)
31. Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009; 204: 483-490.
32. Bulcão C, Ribeiro-Filho FF, Sañudo A, et al. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs. 2007; 7: 219-224. (Pubitemid 47047989)
33. Raji A, Seely EW, Bekins SA, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003; 26: 172-178. (Pubitemid 36929012)
34. Ruggenenti P, Cattaneo D, Loriga G, et al. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension. 2009; 54: 567-574.
35. Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 1894-1900. (Pubitemid 34700615)